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Background: Gastric cancer is a common and highly lethal malignancy in the world, but its pathogenesis remains
elusive. In this study, we focus on the biological functions of CDK-associated Cullin1 (CAC1), a novel gene of the
cullin family, in gastric cancer, which may help us to further understand the origin of this malignancy.
Methods: The AGS and MGC803 gastric cancer cell lines and the GES-1 gastric mucosa cell line were selected for study.
At first, CAC1 expressions of those cell lines were examined by quantitative real-time reverse transcription polymerase
chain reaction (qRT-PCR) and western blot examinations, then CAC1 small interfering RNA (CAC1-siRNA) were designed
and transfected into the AGS cell line with a relatively high level of CAC1. Once CAC1 was silenced, a series of biological
characteristics of AGS cells such as cell proliferation, cell cycle, apoptosis, and expressions of apoptosis-related genes
(P53, BCL2 and BAX) were determined by MTT, flow cytometry, qRT-PCR and western blot, respectively.
Results: CAC1 expression of AGS or MGC803 was much higher than that of GES-1. After CAC1 expression was
effectively depressed by RNA interference in AGS cells, significant cell growth inhibition occurred. Furthermore, the
proportion of cells treated with CAC1-siRNA increased in the G1 phase and decreased in the S phase, indicative of
G1 cell cycle arrest. More importantly, the proportions of early/late apoptosis in AGS cells were enhanced with
cis-diaminedichloroplatinum (cisplatin, CDDP) treatment, but to a higher extent with cisplatin plus CAC1-siRNA.
Interestingly, BCL2 mRNA copies showed about a 30% decrease in the cisplatin group, but dropped by around 60%
in the cisplatin plus CAC1-siRNA group. Conversely, the P53 mRNA expressions obtained nearly a two-fold increase in
the cisplatin group, in addition to a five-fold increase in the cisplatin plus CAC1-siRNA group, and the BAX mRNA
levels had almost a two- and four-fold augmentation, respectively. Meanwhile, P53, BAX and BCL2 showed the same
alteration patterns in western blot examinations.
Conclusions: CAC1 can promote cell proliferation in the AGS gastric cancer cell line. Moreover, it can prevent AGS
cells from experiencing cisplatin-induced apoptosis via modulating expressions of P53, BCL2 and BAX.
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Gastric cancer is one of the most common malignant
tumors and the second leading cause of cancer death in
the world, responsible for a total of 989,600 new cases and
738,000 deaths annually [1]. Over past years, there has
been a steady decline in the incidence and mortality risk of
gastric cancer in most countries [2], due to the tremendous* Correspondence: Nankji@163.com
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reproduction in any medium, provided the ordevelopments in diagnosis and treatment methods. How-
ever, gastric cancer remains a great threat to people, espe-
cially those in developing countries [1], and the survival of
all affected patients, even after curative surgical resection
and adjuvant therapy, is less than 40% [3].
Epidemiologic investigations have uncovered many
risk factors for gastric cancer, and molecular biology re-
search further indicates that gastric carcinogenesis com-
prises numerous genetic and epigenetic events, involving
a cluster of oncogenes, tumor suppressor genes, cell
cycle regulators, cell adhesion molecules and DNALtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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underlying gastric cancer are not well defined.
CDK-associated Cullin1 is a novel gene identified in
colorectal carcinoma. It embraces an open reading frame
sequence which encodes a 37 kDa protein of 369 amino
acids [5]. The CAC1 protein contains a cullin domain be-
tween amino acids 137 and 250, and is therefore classified
as a member of the cullin family of E3 ubiquitin ligases [5].
Histological investigations had established a possible asso-
ciation of CAC1 expression with pathological features and
clinical stages of colorectal carcinoma patients [5]. More-
over, CAC1, in vitro, was expressed in a cell cycle-
dependent manner with high expression in the late G1 to
S phase [5]. Notably, CAC1 could promote cell cycle pro-
gression and stimulate the kinase activity of CDK2 [5].
Nevertheless, little is known about its expression and bio-
logical characteristics in gastric cancer.
The present study was conducted to investigate the ex-
pression of CAC1 and to explore the function that CAC1
performs in gastric carcinoma cell lines. The AGS cell line
was selected as the model for study because it expressed
relatively high level of CAC1, then CAC1 expression was
silenced by RNA interference (RNAi), and a series of bio-
logical parameters relevant to cell proliferation, cell cycle
and apoptosis were examined, correspondingly.
Methods
Cell culture
Human gastric cancer cell lines (AGS and MGC803)
and gastric mucosa cell line (GES-1) were provided by
Central Laboratory of Medical College, Xi’an Jiaotong
University, China. Cells were cultured in RPMI 1640
medium (Gibco BRL, Grand Island, NY, USA) supple-
mented with 10% newborn calf serum (Gibco BRL,
Grand Island, NY, USA), 100 kU/L penicillin, 0.1 g/L
streptomycin, 0.3 g/L L-glutamine and 0.85 g/L NaHCO3
at 37°C in a humidified atmosphere containing 5% CO2.
siRNA transfection
CAC1-siRNA (sense-GGA UGG UGC CAU AGA UCA
ATT 30, antisense-50UUG AUC UAU GGC ACC AUC
CGG30), CAC1 negative control siRNA (NC-siRNA,
sense-50UUC UCC GAA CGU GUC ACG UTT 30,
antisense-50ACG UGA CAC GUU CGG AGA ATT 30)
were chemically synthesized by Shanghai GenePharma
Corporation (SGC, Shanghai, China). All siRNAs were
mixed into Lipofectamine2000 (Invitrogen, Carlsbad,
California, USA) and transfected according to the siRNA
Transfection Protocol. The efficiency of CAC1 knockdown
was evaluated with qRT-PCR and western blot tests.
MTT assay
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide thiazolyl blue indicator dye)chemosensitivity assay was applied to determine the
proliferation rate of AGS gastric cells. Cells were
seeded at a concentration of 5 × 103 cells per well in
96-well plates. All experiments were conducted in
triplicate. Cells were incubated for 24 hours and
were divided into five groups with five different
treatments (null, NC-siRNA (60 nmol/L(nM)), siRNA
(30nM), siRNA (60nM), siRNA (90nM)) for 0, 24, 48,
72 and 96 hours, correspondingly. Twenty microliters
of 5 mg/ml MTT (Sigma Chemical Co, St. Louis,
MO, USA) in phosphate buffered saline (PBS) were
added per well and cells were left inside the incuba-
tor for another 4 h at 37°C, followed by the addition
of 150 μl DMSO. Absorbance of the colored solution
was measured by a fully automated multi-detection
microplate reader (POLARstar OPTIMA, BMG Lab-
technologies, Offenburg, Germany) at 490 nm.
Flow cytometric analysis
Cells (1 × 105 cells/well) were harvested in 6-well plates
for 24 hours, and were treated with different agents
(null, NC-siRNA, siRNA (60nM)) for 48 hours. Then
they were collected to be washed with 0.01 mol/L cold
(4°C) PBS by spinning at 800 rpm, 4°C for 8 minutes,
and then fixed in 4°C, 75% ethanol for a night. Fixed
cells were centrifuged (as above) and washed again with
PBS. Then cells were treated with 100 μl of DNase-free,
RNaseA (10 mg/ml) and incubated at 37°C for 10 min-
utes. Finally, cells were stained with 100 μl of 100 μg/ml
propidium iodide (light sensitive) and incubated at room
temperature for 30 minutes. Cells from every sample
were placed in Falcon tubes and read on a FAC sorter
(Becton Dickinson, Franklin Lakes, NJ, USA). The cell
cycle profiles were interpreted with B-D FAC Sort Cell
Quest software.
Apoptosis analysis
Cells (1 × 105 cells/well) were incubated in 6-well plates.
After 24 hours, they were addressed with different
agents (null, cisplatin (10 μM), cisplatin (10 μM) +NC-
siRNA (60nM), cisplatin (10 μM) + siRNA (60nM)) in
serum-free medium for 24 hours, then collected cells
were stained with Annexin V/PI using Vybrant apoptosis
assay kit No. 2 (Molecular Probes, Eugene, Oregon,
USA) and analyzed by flow cytometry.
Quantitative real-time reverse transcription PCR
Expression of CAC1 in gastric cancer cell lines
Total RNA was isolated from various cell lines (AGS,
MGC803 and GES-1) using the acid guanidinium-
phenol-chloroform method (Trizol, Invitrogen, Carlsbad,
USA), and cDNAs were synthesized using the Prime-
ScriptTM 1st Strand cDNA Synthesis Kit (Invitrogen,
Carlsbad, USA). Primer sequences used for amplification
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and listed as follows: forward primer 5'-GCA GCA TAT
TCA GAA AGT TCA GA-3'; reverse primer 5'-CAT
TTA CAG CCT AAT GCC TTT ACT-3'. β-Actin for-
ward primer 5'- TGG CAC CCA GCA CAA TGA A -3';
reverse primer 5'- CTA AGT CAT AGT CCG CCT
AGA AGC A -3'. Primers were used in regular PCR
reactions with cDNA from cells so as to evaluate their
proper design and synthesis. Subsequently, the PCR pro-
ducts were sequenced and their similarity to the desired
nucleotide sequences confirmed. The relative amount of
mRNA was determined using the SYBR GREEN PCR Mas-
ter Mix (AB, Applied Biosystems, Foster City, California,
USA) with gene-specific primers for CAC1 or β-Actin. All
steps were carried out according to the manufacturer’s
protocol. Real-time PCR reactions were carried out on an
ABI 7500 thermal cycler (Applied Biosystems, Foster
City, California, USA) with the BioRad iQ5 and MyiQTM
Real-time PCR Detection System (BioRad Laboratories,
Hercules, California, USA). Three independent PCR tests
were performed from each RT sample. The expression
of CAC1 mRNA in each sample was normalized against
β-actin and the expression level was calculated using the
ΔΔCT (delta delta threshold cycle) method.
Expression of apoptosis-related genes in AGS cell line
RNA isolation and cDNA synthesis were performed as
noted. A series of primers were designed and synthesized
by TaKaRa including P53 (forward-50-CCA CCA TCC
ACT ACA ACT ACA T-30, reverse-50-AGG ACA GGC
ACA AAC ACG-30), BCL2 (forward-50-CAA ATG CTG
GAC TGA AAA ATT GTA-30, reverse-50-TAT TTT
CTA AGG ACG GCA TGA TCT-30), BAX (forward-50-
GAC ACC TGA GCT GAC CTT GG-30;reverse-50-AGG
AAG TCC AGT GTC CAG C-30) and β-Actin (forward
50-TGG CAC CCA GCA CAA TGA A-30; reverse 50-
CTA AGT CAT AGT CCG CCT AGA AGC A −30)
genes. As indicated above real-time PCR was performed
three times.. The PCR products were detected by meas-
uring the emitting fluorescence at the end of each reac-
tion cycle. The threshold cycle corresponds to the
number of cycles required to detect a fluorescence signal
above the baseline. The β-Actin gene served as the in-
ternal control of the reaction.
The mRNA expression levels were calculated using the
2-ΔΔCT method and expressed in relative quantification
units. In detail, the threshold cycles of the housekeeping
gene β-Actin and the target genes BCL2, BAX and P53
were determined in each sample and for each time
period. CT values were normalized (ΔCT) by subtracting
the expression levels of the reference gene β-Actin from
the corresponding expression levels of the BCL2, BAX
and P53 in each sample. The normalized gene expres-
sion in the treated AGS cells was analyzed relative totheir matching untreated cells, which acted as calibrator
samples (ΔΔCT).
Western blot examinations
Fifty micrograms of total protein from the AGS cell line
was separated on a 10% Trisglycine SDS polyacrylamide
gel and transferred to a nitrocellulose membrane
(BioRad, Hercules, California, USA). The blot was
probed with mouse monoclonal antibodies including
anti-CAC1 (GeneTex, Irvine, California, USA, 1:1500),
anti-β-Actin (Santa Cruz, CA, USA; 1:5000), anti-P53
(Santa Cruz, CA, USA; 1:2000), anti-BCL2 (Santa Cruz,
CA, USA; 1:2000), and anti-BAX (Santa Cruz, CA,
USA; 1:2000). Antibody binding was detected using the
Gel Blot Imaging Systems (Syngene G:BOX, Cambridge,
U.K.) according to the manufacturer’s protocol.
Statistical analyses
All statistical analyses were conducted using SPSS
13.0 software (http://www-01.ibm.com/software/analytics/
spss/). Each assay was performed at least three times. The
data were expressed as mean ± standard deviation, and
One-way ANOVA test (two-sided) was performed to deter-
mine the significance of differences in multiple compari-
sons. The results were considered to be statistically
significant at P <0.05.
Results
Differential expression of CAC1 in gastric cancer and
mucosal cell lines
CAC1 mRNA expression was evaluated with real-time RT-
PCR in three cell lines. Obviously, CAC1 was expressed in
each of the examined cell lines (Figure 1A). However, AGS
and MGC803 cell lines showed higher levels of CAC1
mRNA than the GES-1 cell line (1.0000 ± 0.0000 and
0.9507 ± 0.0176 versus 0.4340 ± 0.0414, P <0.05). In
addition, CAC1 protein expression in western blot
examinations showed the same changing trend as
CAC1 mRNA (Figure 1A).
Endogenous expression of CAC1 was silenced by the RNAi
technique
Transient transfection of AGS cells with CAC1-siRNA
oligos (60nM) designed against CAC1 sequence effect-
ively inhibited the expression of CAC1. CAC1 mRNA
expression was examined by real-time RT-PCR. As
expected, mRNA level of CAC1 was considerably
decreased in CAC1-siRNA group (1.0000 ± 0.0000 ver-
sus 0.3583 ± 0.0244, P <0.05), but showed no signifi-
cant difference between the control and NC-siRNA
groups (1.0000 ± 0.0000 versus 0.9597 ± 0.0407, P >0.05)
(Figure 1B). Meanwhile, CAC1 protein expression was
also depressed after siRNA treatment in western blot
examinations (Figure 1B).
Figure 1 CAC1 expression in human gastric cancer and mucosal cell lines. (A) Real-time reverse transcription (RT)-PCR and western blot
analysis of CAC1 expression in AGS, MGC803 and GES-1 cell lines (*represents P <0.05 between the GES-1 cell line and other cell lines). (B) CAC1
expression was effectively depressed by 60nM CAC1-siRNA in the AGS cell line on the mRNA and protein level (*represents P <0.05 between the
control group and the CAC1-siRNA group).
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In order to investigate the role CAC1 plays in the regula-
tion of cell proliferation, AGS cells addressed by transi-
ent transfection with CAC1-siRNA of three different
dosages (30nM, 60nM and 90nM) were subjected to
MTT assay. Within four days, CAC1 silencing exhibited
a distinct inhibitory effect on cell proliferation according
to different doses of CAC1-siRNA (Figure 2). Optical
densities (ODs) of the control group, the NC-siRNA
group and the 30nM CAC1-siRNA group showed no sig-
nificant difference with each other (P >0.05), but were
higher than those of the 60nM and 90nM CAC1-siRNA
groups (P <0.05). Interestingly, cells treated with 60nM
and 90nM CAC1-siRNA showed almost identical ODs
from the beginning to the end (P >0.05).
Cell cycle analysis
Compared with the control, the proportion of cells treated
with CAC1-siRNA increased by 28% or so in the G1/G0
phase (45.33% ± 0.82% versus 73.23% ± 3.04%, P <0.05),
and decreased by approximately 36% in the S phase
(41.07% ± 1.07% versus 5.40% ± 5.83%, P <0.05), with nosignificant change in the G2/M phase (13.61% ± 0.46% ver-
sus 21.37% ± 2.88%, P >0.05) (Figure 3). These results indi-
cate that CAC1 may promote cell cycle progression of
AGS cells through the G1/S transition.
Knockdown of CAC1 enhances cisplatin-induced apoptosis
The AGS cells were divided into four experimental
groups: the control group, the cisplatin-treated (10 μM)
group, the cisplatin plus NCsiRNA group, and the cis-
platin plus CAC1-siRNA (60nM) group. Compared with
the control group, the proportions of early/late apop-
tosis were enhanced with cisplatin treatment, but to a
higher extent with cisplatin plus CAC1-siRNA (2.01% ±
0.78% versus 8.87% ± 3.65% versus 16.69% ± 3.15%/
0.57% ± 0.25% versus 3.89% ± 0.15% versus 10.01% ±
0.09%, P <0.05) (Figure 4A and 4B), which signified
that the knockdown of CAC1 dramatically acceler-
ated cisplatin-induced apoptosis.
Expression profiles of apoptosis-related genes
The mRNA levels of CAC1, BCL2, BAX and P53 were
examined by qRT-PCR. Incubation of the AGS cells with
Figure 2 Cell growth was inhibited following CAC1 silencing. AGS cells were transiently transfected with null, NC-siRNA and three
concentrations of CAC1-siRNA for four days, respectively. Growth rates of cells were determined by MTT assays.
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produce interesting mRNA profiles (Figure 5A). Under
cisplatin treatment, CAC1 mRNA expression greatly
increased, but dropped to a low level when CAC1-siRNA
was added simultaneously (1.0000 ± 0.0000 versus
2.1578 ± 0.2222 versus 0.3967 ± 0.0078, P <0.05). Com-
pared with the control group, BCL2 mRNA copies
showed a 30% decrease in the cisplatin group, but
dropped by around 60% in the cisplatin plus CAC1-
siRNA group (1.0000 ± 0.0000 versus 0.7090 ± 0.0210
versus 0.4030 ± 0.0171, P <0.05). Conversely, P53 and
BAX transcript levels of treated groups were vastly
enhanced. Compared with the control group, the P53
expression obtained nearly a two-fold increase in the cis-
platin alone group, in addition to a five-fold increase in
the cisplatin plus CAC1-siRNA group (1.0000 ± 0.0000
versus 3.0187 ± 0.1738 versus 5.9957 ± 0.3926, P <0.05);
the BAX mRNA levels had almost a two- and four-fold
augmentation (1.0000 ± 0.0000 versus 3.0237 ± 0.2581
versus 4.9897 ± 0.2923, P <0.05), respectively.
Then western blot tests were conducted to detect
the protein levels of those genes after CAC1 knock-
down. In parallel with the aforementioned mRNA
changes, BAX and P53 were markedly upregulated
whereas BCL2 was downregulated on the protein level
(Figure 5B).Discussion
The ubiquitin-proteasome system plays a pivotal role
in maintaining the balance between normal growth
and uncontrolled proliferation by controlling the
abundance of a large variety of cellular proteins [6].
The cullin family of ubiquitin ligases, traditionally
composed of CUL1, 2, 3, 4A, 4B, 5 and 7, represents
the largest class of RING-type E3 ligases (CRLs) [6].
Without intrinsic catalytic activity, cullins serve as
scaffolds that facilitate the assembly of multimeric E3
ligase complexes and transfer ubiquitin from the E2-
conjugating enzyme to the substrate. Cullin-mediated
substrate degradation dictates a wide range of cellular
processes such as proliferation, differentiation, and
apoptosis. Once the cell regulatory mechanisms of
cullin encounter malfunctions or perturbations, accu-
mulation of oncoproteins or excessive degradation of
tumor suppressors will inevitably occur, which may
provoke cells into malignant transformation and
tumorigenesis [6]. In particular, cullin1, the most
characterized member of the cullin family, was proven
to be closely associated with gastric carcinogenesis,
and its overexpression predicts poor prognosis of
patients with gastric carcinoma [6,7].
The expression profiles of cancer-related genes in part
reflect their biological features in the pathogenesis of
Figure 3 Knockdown of CAC1-induced G1 cell cycle arrest in the AGS cell line. Cell cycle analysis of AGS cells treated with or without CAC1-
specific siRNA by flow cytometry. Proportion of cells was markedly elevated in the G1 phase while reduced in the S phase when treated with
CAC1-siRNA (*represents P <0.05 between the control group and the CAC1-siRNA group).
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expression patterns have been extensively investigated in
a previous study [5]. Using cDNA library analysis, CAC1
expression was found in normal stomach, small intes-
tine, colon, liver, lung, kidney, muscle, heart, mammary
gland, uterus, brain, spleen, lymph node, with high levels
in the colon and mammary gland [5]. Western blot tests
additionally detected CAC1 protein in a host of normal
and cancer cell lines [5]. With regard to our study, the
AGS and MGC803 gastric cancer cell lines had higher
CAC1 expression than the GES-1 gastric mucosal cell
line, which indicate that CAC1 may play an active role
in gastric carcinogenesis.
Gene silencing by RNA interference is a powerful
method for analyzing gene function [8]. Here, wesuccessfully transfected NCsiRNA and three concentra-
tions of CAC1-siRNA into AGS cells. MTT analyses
showed that the proliferation potential of AGS cells was
potently inhibited by 60nM and 90nM CAC1-siRNA to
the same degree, but failed to be influenced by 30nM
CAC1-siRNA or NC-siRNA. It was apparent that CAC1
could positively affect cell proliferation in gastric cancer,
which was in accord with previous studies on the HeLa
cell line [5]. In MTT examinations, HeLa cells expres-
sing Flag-CAC1 underwent higher proliferation ability
than the mock transfected control cells, and cells treated
with CAC1-siRNA showed significantly inhibited growth
rate [5]. What’s more, real-time RT-PCR and western
blot analyses confirmed that the expression of CAC1
was efficaciously blocked by 60nM CAC1-siRNA. Taken
Figure 4 (See legend on next page.)
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Figure 4 CAC1 silencing enhanced cisplatin-induced apoptosis in AGS cell line. (A) The effects of cisplatin alone and in combination with
NC-siRNA/CAC1-siRNA on early and late apoptosis of AGS cells (*represents P <0.05 between control group and treated groups; #represents
P <0.05 between the cisplatin (CDDP) group and other treated groups). (B) Apoptosis patterns of AGS cells were analyzed by flow cytometry.
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perimental dosage for RNAi in subsequent examinations.
As a general rule, normal cell proliferation depends on
orderly and efficient cell cycle process that ensures the
duplication and transmission of genetic information
from one cell generation to the next. In other words, de-
regulation of cell proliferation always lies in an abnormal
cell cycle. Under CAC1-silencing conditions, flow cyto-
metry in our study revealed elevated proportion of cells
in the G1/G0 phase and a reduced rate of cells in the S
phase. In essence, CAC1 knockdown induced G1 cell
cycle arrest in the AGS cells, which was consistent with
the results from the HeLa cell line [5]. CAC1 was also
capable of binding to CDK2 and stimulating its kinase
activity at the G1/S phase transition without greatly
changing the expressions of cyclinA, cyclinE, cyclinD1,
CDK2, RB, PTEN, and so on [5]. It is supposed that
CAC1 depression attenuates the activity of CDK2 and
interrupts the G1-S transition.
Apoptosis is one of the basic biological phenomena
characterized by a series of transformations in cell
morphology [9]. Furthermore, apoptosis in concert with
cell proliferation forms a crucial balancing mechanism
that manages a large number of physiological procedures
such as tissue homeostasis and normal development [9].
Under pathological circumstances, aberrant apoptosis
usually contributes much to the initiation and progres-
sion of cancer [10-12] and even influence the sensitivity
of cancer cells to therapeutic interventions [13].
The unequivocal activity of CAC1 in cell cycle regula-
tion raised the possibility that it is, more or less, involved
in the process of apoptosis. In the current study, the pro-
portion of early/late apoptotic cells increased with cis-
platin treatment, but increased even more so when
CAC1 expression was concurrently inhibited by RNAi.
That is to say, apoptotic indices of the cisplatin plus
CAC1-siRNA group obtained a significant increase in
comparison with those of the former three groups with
intact CAC1. Cumulative data imply that CAC1 may
weaken the anti-cancer effect of cisplatin by counteract-
ing cisplatin-induced apoptosis.
Regulation of apoptosis, however, relies on a network
of anti- and proapoptotic molecules such as BCL2 family
[14]. BCL2 (B cell CLL/lymphoma 2) is a proto-
oncogene located in the chromosomal region 18q21.3,
which codes for an antiapoptotic 26-kDa protein con-
taining four BH domains (BH1 ~ BH4)) [15]. It can hin-
der the release of cytochrome c from the mitochondria,
thus abrogating the activation of caspases and finallyinhibiting apoptosis [16]. According to early studies, the
overexpression of BCL2 drives cells toward malignant
transformation [17] and predicts the prognosis in many
malignancies [18-22]. Particularly in gastric cancer, fre-
quent expression of the BCL2 gene always occurred in
malignant tissues [23-25]. High expression levels of the
BCL2 gene, though correlated with less aggression of
stomach cancer [26], had a lot to do with drug resistance
of the cancer cells [27].
BAX (BCL2 associated X protein) gene is located in
the human chromosomal region 19q13.3-q13.4 [28]. Its
21-kDa encoding protein, in particular, serves as a proa-
poptotic member of the BCL2 family. BAX protein con-
sists of three BH domains (BH1, BH2, and BH3) and
shares a lot of homology with the BCL2 protein. Indeed,
BAX protein acts as a suppressor of BCL2 to accelerate
apoptotic cell death, by forming BAX/BCL2 complexes
or by competing with other BCL2 targets [29]. Overex-
pression of the BAX gene had a negative effect on cell
growth in human gastric cancer, owing to the induction
of apoptosis and to the enhancement of cell chemosensi-
tivity [30]. On the contrary, suppression of BAX gene ex-
pression induced tumorigenesis in gastric epithelia [23].
Cisplatin is a kind of chemotherapeutic agent widely
used in solid malignancies including gastric cancer. It is
generally accepted that its primary cytotoxic effect is
DNA damage and subsequent induction of apoptosis
[31], so variances of apoptosis-associated genes in cis-
platin treated cells penetratingly mirror the mechanisms
underlying cisplatin-induced apoptosis. As for our study,
CAC1 expression was upregulated by cisplatin treat-
ment, but was markedly downregulated by siRNA treat-
ment despite previous cisplatin. Furthermore, underlying
the increase of cisplatin-induced apoptosis that
follows CAC1 silencing are concomitant gene expres-
sion alterations including the upregulation of P53
and BAX as well as the downregulation of BCL2.
These effects suggest that CAC1 strengthens cisplatin-
induced apoptosis by modulating the expression of BCL2,
BAX and P53.
As mentioned previously, BCL2 is seemingly situated
at the convergence of a couple of apoptotic pathways,
and the ratio of BCL2 to BAX protein appears to be the
final determinant of whether a cell enters the execution
phase [31]. In fact, it is the BCL2/BAX ratio that governs
the sensitivity of cells to apoptotic stimuli [32,33]. In the
process of cisplatin-induced apoptosis, CAC1 might pro-
tect AGS cells from apoptosis by altering BCL2/BAX
ratio, for CAC1 silencing brought out a pronounced
Figure 5 Expression profiles of apoptosis-related genes in response to cisplatin alone or with CAC1-siRNA treatments. (A) Real-time
reverse transcription (RT)-PCR analysis of CAC1, P53, BAX and BCL2 mRNA expression in AGS cells (*represents P <0.05 between CAC1-siRNA group
and treated groups; #represents P <0.05 between the cisplatin (CDDP) group and other treated groups). (B) Western blotting analysis of CAC1,
P53, BCL2 and BAX expression in AGS cells.
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ducive to the occurrence of cell apoptosis.
Interestingly, the P53 gene in the AGS cells was upre-
gulated with the cisplatin treatment, especially with syn-
chronous suppression of CAC1. It is well known that
P53 plays an important role in the management of cell
cycle and apoptosis. DNA damage resulting from cis-
platin may stimulate expression of the P53 protein that
results in both expression of downstream P21 protein
and G1 cell cycle arrest [34]. If confronted with irrepar-
able DNA damage, the P53 protein triggers programmed
cell death [31]. During cell apoptosis, P53 activates BAX
via transcriptional [35] or transcription-independent [36]
mechanisms, and represses transcription of BCL2 [14].
Furthermore, P53 can nontranscriptionally induce apop-
tosis [37]. Therefore, CAC1 inhibition in the AGS cells
can bring about excessive P53 accumulation, BAX accu-
mulation, and BCL2 reduction, which ultimately poten-
tiated apoptosis.
The mechanism by which CAC1 functions is not fully
clarified. CAC1 was able to reinforce the activity of
CDK2 [5], and CAC1 silencing probably impaired the
CDK2 activity. An early study argued that CDK2 inhib-
ition could lead to ATM- and ATR-dependent P53 phos-
phorylation at serine 15, and thereby cause a significant
increase of P53 and P21 protein [38]. With the potential
to activate CDK2, CAC1 is inclined to interfere with the
P53-P21 pathway, and thus help AGS cells to resist G1
arrest and apoptosis. On the other hand, CAC1 can
serve as a corepressor of RARα to negatively regulate
retinoid acid-induced cellular differentiation and CoRNR
box is confirmed to be a major functional region of
CAC1 [39]. So it seems that CoRNR box has the poten-
tial to regulate cell proliferation and apoptosis, which
deserves to be further investigated in other studies.Conclusion
In summary, CAC1 exerts multiple biological effects in the
AGS gastric carcinoma cell line. Through promoting pro-
liferation and by countering cisplatin-induced apoptosis,
CAC1 has been deeply implicated in the pathogenesis and
development of gastric cancer. More explorations on spe-
cific details of the molecular mechanisms are warranted in
the future.
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